The 23 references in paper S. AL-SHUKRI H., I. KUZMIN V., С. АЛЬ-ШУКРИ Х., И. КУЗЬМИН Н. (2011) “ПРОСТАГУТФОРТЕ В ЛЕЧЕНИИ ДОБРОКАЧЕСТВЕННОЙ ГИПЕРПЛАЗИИ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ // PROSTAGUT-FORTE IN BENIGN PROSTATIC HYPERPLASIA TREATMENT” / spz:neicon:nefr:y:2011:i:3:p:45-50

1
Гориловский ЛМ. Эпидемиология, факторы риска развития и биологическое течение доброкачественной гиперплазии предстательной железы. В: Лопаткин НА, ред. Доброкачественная гиперплазия предстательной железы. М., 1999; 12-20
(check this in PDF content)
2
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. Изменение значений основных клинических показателей ДГПЖ в процессе лечения простагутом-форте (в % от суммарного изменения значения показателя к окончанию лечения). J Uro 1984;132:474-479
(check this in PDF content)
3
Stovsky MD, Rhee K, Hartke D. Medical therapy versus surgery and minimally invasive surgical therapies for lower urinary tract symptoms and benign prostatic hyperplasia: what makes better economic sense? Curr Urol Rep 2007;8(4):289297
(check this in PDF content)
4
McConnell JD. Prostatic growth: new insights into hormonal regulation. Br J Urol 1995;76[suppl 1]: 5-10
(check this in PDF content)
5
Lepor H. Pathophysiology, Epidemiology, and Natural History of Benign Prostatic Hyperplasia. Rev Urol 2004; 6 [suppl 9]: S3-S10
(check this in PDF content)
6
Walsh PC, Hutchins GM, Ewing LL. Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supernormal. J Clin Invest 1983;72:1772-1777
(check this in PDF content)
7
Nickel JC. Inflammation and Benign Prostatic Hyperplasia Urol Clin North Am 2008; 35(1): 109-115
(check this in PDF content)
8
Robert G, Salagierski M, Schalken JA, de La Taille A. Inflammation and benign prostatic hyperplasia: cause or consequence? Prog Urol 2010 ;20(6):402-407
(check this in PDF content)
9
Roberts RO, Lieber MM, Rhodes T et al. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urol 1998;51:578-584
(check this in PDF content)
10
Collins MM, Meigs JB, Barry MJ et al. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol 2002;167(3):1363-1366
(check this in PDF content)
11
Nickel JC, Roehrborn CG, O’Leary MP et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. J Urol 2007;177[suppl 14]: 34-35
(check this in PDF content)
12
Buck AC. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 2004;172:1792-1799
(check this in PDF content)
13
St Sauver JL, Jacobson DJ, McGree ME et al. Association between prostatitis and development of benign prostatic hyperplasia. J Urol 2007;177[suppl 4]: 497
(check this in PDF content)
14
Kramer G, Marberger M. Could Inflammation be a key component in the progession of benign prostatic hyperplasia? Curr Opin in Urol 2006;16:25-29
(check this in PDF content)
15
Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 1979;121:755-760
(check this in PDF content)
16
Kramer G, Steiner GE, Handisurya A et al. Increased expression of lymphocyte- derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002;52: 43-48
(check this in PDF content)
17
Lee KL, Peehl D. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004;172:1784-1791
(check this in PDF content)
18
Kramer G, Mitteregger H, Marberger M. Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease? Europ Urol 2007;51:1202-1216
(check this in PDF content)
19
Lopatkin N, Sivkov A, Walther C et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, doubleblind, multicenter trial. World J Urol 2005; 23(2):139-146
(check this in PDF content)
20
Лопаткин НА, Сивков АВ, Медведев АА и др. Комплексное лечение больных аденомой предстательной железы с использованием Простагут форте. Урология 2006; (2):12, 14-19
(check this in PDF content)
21
Engelmann U, Walther C, Bondarenko B et al. Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittelforschung 2006;56(3):222-229
(check this in PDF content)
22
Lopatkin N, Sivkov A, Schlafke S et al. Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms — long-term follow-up of a placebocontrolled, double-blind, multicenter trial. Int Urol Nephrol 2007; 39(4):1137-1146
(check this in PDF content)
23
Неймарк АИ, Давыдов АВ. Комплексное лечение больных аденомой предстательной железы с использованием Простагут форте. Русский медицинский журнал 2008; 29:2010-2011 Ïîñòóïèëà â ðåäàêöèþ 04.04.2011 ã.
(check this in PDF content)